Skip to content
Open access

Comparative Effects of Metformin and GLP-1 Agonists on Polyendocrine Metabolic Ovary Syndrome and Gallbladder Disease

Oct 2026 · Georgetown Medical Review · Vol 10 · 0 citations · 19 references

TL;DR

Glucagon-like peptide-1 RAs were associated with a lower incidence of cholelithiasis and cholecystitis than metformin than metformin, whereas cholangitis rates were similar.

Abstract

Polyendocrine metabolic ovarian syndrome (PMOS) is a common endocrine disorder affecting 5% to 15% of reproductive-aged individuals and is frequently accompanied by hyperinsulinemia and obesity. These metabolic disturbances contribute to gallbladder dysmotility and increased cholesterol synthesis, elevating the risk of cholelithiasis, cholecystitis, and cholangitis. Metformin is widely used to manage dyslipidemia, type 2 diabetes mellitus, and obesity in patients with PMOS, but emerging therapies such as glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) may offer additional benefit. This study used the TriNetX network to compare the incidence of gallbladder disease between patients with PMOS treated with metformin and those treated with GLP-1 RAs. After 1:1 propensity score matching on age, type 2 diabetes mellitus, obesity, body mass index, and lipid-lowering therapy, two cohorts of 53,258 patients were analyzed. Glucagon-like peptide-1 RAs were associated with a lower incidence of cholelithiasis and cholecystitis than metformin, whereas cholangitis rates were similar. These findings suggest that GLP-1 RAs may confer a protective effect through weight reduction and improved insulin sensitivity. Further study is warranted to confirm the effect of GLP-1 RAs on cholelithiasis and cholecystitis.

Read PDF

Similar papers

Review Open access Oct 2026

The Impact of Incretin-Based Therapies on Anthropometric and Metabolic Parameters in Women with Polyendocrine Metabolic Ovarian Syndrome

Abstract Polycystic ovary syndrome (PCOS), recently renamed polyendocrine metabolic ovarian syndrome (PMOS), affects 170 million women globally and is often accompanied by obesity and various levels of insulin resistance. Incretin-based therapies, including the glucagon-like peptide-1 (GLP-1) receptor agonists liraglut...

Andrijana Koceva, A. Janež, M. Jensterle · 0 citations
Review Open access Oct 2026

From PCOS to PMOS: insulin resistance, obesity, and the role of GLP-1 receptor agonists in stepwise therapy

Background. In 2026, an international consensus endorsed a new name for polycystic ovary syndrome (PCOS) – "polyendocrine-metabolic ovarian syndrome" (PMOS). The new nomenclature reflects the systemic and pathogenetically heterogeneous nature of the disorder, in which abnormalities of ovulation and steroidogenesis coex...

O. A. Pustotina · 0 citations
Open access Oct 2026

Preconception incretin therapy reduces pregnancy and cardiometabolic outcomes in polycystic ovary syndrome.

Pre-conception GLP-1/GIP RA use in women with PCOS/PMOS was associated with lower risks of adverse pregnancy outcomes and cardiometabolic disease compared with metformin, consistent with potential benefits of pre-conception metabolic optimisation.

A. Henney, Phoebe J. Holmes, David R. Riley et al. · 0 citations
Review Open access Oct 2026

Metabolic, hormonal, and reproductive effects of GLP-1 receptor agonizts in hyperandrogenic insulin-resistant women: a systematic review.

CONTEXT Hyperandrogenic insulin-resistant states, most commonly polycystic ovary syndrome (PCOS) and severe phenotypes such as HAIR-AN syndrome, are characterized by metabolic dysfunction, androgen excess, and reproductive disturbance. Insulin resistance is a central pathogenic driver and therapeutic target. OBJECTIV...

Mariam Sherif Mohamed, A. Farrag, Panayoti Bachkangi · 0 citations
Open access Oct 2026

GLP-1 receptor agonists and adverse outcomes in patients with type 2 diabetes and chronic viral hepatitis.

Background/Aims Glucagon-like peptide-1 receptor agonists (GLP-1RA) are a novel class of anti-diabetic drugs that can treat obesity and type 2 diabetes (T2D). T2D and chronic viral hepatitis (CVH) frequently coexist and worsen liver and non-liver outcomes, but effective pharmacological therapies are limited. We aimed t...

Xin-Rong Zhang, Xian-Hua Mao, Scott Barnet et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.